 Shares of small-cap biotech Arbutus Biopharma Corporation NASDAQ: ABUS are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals Board has turned down Moderna, Inc.s NASDAQ: MRNA appeal to invalidate two of Arbutus patents on drug-delivery technology used in the formers COVID-19 vaccine. 